Annexon Biosciences

This week, our team is in Ft. Lauderdale, FL for Retina World Congress with two poster presentations on our potential treatment for geographic atrophy, vonaprument. Vision Outcomes in Eyes with Subfoveal RPE Lesions in Geographic Atrophy: A Post Hoc Analysis of the Phase 2 ARCHER Trial - Dr. Jordana Goren Fein Clinical Rationale for Loss of 15 or More ETDRS Letters in Eyes with Dry AMD and GA: Analysis of the Phase 2 ARCHER Visual Acuity Outcomes - Dr. David Chin Yee Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) and is a leading cause of irreversible vision loss in developed countries. Annexon’s vonaprument is currently in a global Phase 3 clinical trial as a potential vision-preserving treatment for GA. If you're onsite in Ft. Lauderdale, stop by and see us at booth #17! #RetinaWorldCongress 

In recognition of GBS Awareness Month, Annexon is proud to partner with the GBS|CIDP Foundation International to support the GBS: 110 Years, 110 Stories campaign. This year marks 110 years since Guillain-Barré syndrome was first identified. GBS is a sudden, life-altering, neuromuscular condition that can strike anyone, anywhere, at any time. It impacts over 150,000 patients and their families worldwide every year. Through this campaign, 110 patient stories will be shared throughout 2026 to raise awareness, highlight the lived experience of GBS, and reinforce the need for continued research and improved care. We are honored to support this effort and help bring greater visibility to the voices of those affected by GBS. https://lnkd.in/egY-FnVg

Thank you to everyone who connected with Annexon at the 2026 American Academy of Neurology Annual Meeting. This year’s meeting was an important opportunity to contribute to the scientific dialogue around Guillain-Barré syndrome through four presentations, including an oral presentation and poster session discussions spanning disease burden, patient experience, and data related to targeted C1q inhibition. Across presentations and conversations throughout the meeting, one theme remained clear: GBS continues to carry significant short- and long-term consequences for patients, underscoring the need for timely diagnosis, improved care coordination, and more effective treatment approaches. We appreciate the engagement from clinicians, investigators, and the broader neurology community. Presentations are available on our website here: https://lnkd.in/gTpr7NBW

We’re in Chicago this week for the 2026 American Academy of Neurology Annual Meeting. This afternoon Annexon’s Henk-André Kroon will be presenting on Phase 3 results evaluating investigational tanruprubart in Guillain-Barré syndrome. Be sure to check it out if you’re on site. GBS is a life-altering, rapid-onset neuromuscular emergency that can lead to serious short- and long-term consequences despite current treatment approaches. We are proud to contribute to the scientific dialogue with data aimed at advancing understanding of this significant unmet need.

We’ve released our fourth quarter and full-year 2025 financial results, along with updates across our portfolio and key anticipated milestones ahead. “We’re energized by this defining period for Annexon. Two decades of C1q and classical complement pathway research have enabled our bold mission of pioneering a new class of targeted immunotherapies that reshape how neuroinflammation is treated. Today, our scientific platform has translated into two late-stage registrational programs with the potential to improve the lives of millions in large, underserved markets worldwide,” said Douglas Love, president and chief executive officer of Annexon. Read more about our progress in the full press release: https://lnkd.in/ewRArEvD

Last week we had the pleasure of hosting a group of investors and analysts in New York for a series of presentations on dry AMD with geographic atrophy (GA) and our investigational medicine vonaprument. Featuring retina specialist KOLs, Dr. Eleonora (Nora) Lad and Dr. Charles Wykoff as well as senior leaders from Annexon, the discussion highlighted the science of GA and the role of C1q, the clinical data to date for vonaprument, and what meaningful vision preservation could mean for patients and their families. The webcast replay is now available via our website: https://lnkd.in/epXDrhNa

We’re looking forward to participating in the TD Cowen 46th Annual Health Care Conference. Our President and CEO, Douglas Love, will share an update on Annexon’s targeted immunotherapy platform and the progress we’re making in advancing therapies for serious neuroinflammatory diseases. Read the full announcement here: https://lnkd.in/eYip3g6s

We're looking forward to the 44th Annual J.P. Morgan Healthcare Conference next week. Our President and CEO, Douglas Love, will present an update on Annexon’s progress and the exciting year ahead on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast will be available on our website: https://lnkd.in/e7Yctigq #JPM2026

Today, we announced the submission of a Marketing Authorization Application to the European Medicines Agency for tanruprubart for the treatment of Guillain-Barré syndrome. This is an exciting milestone for Annexon and the 150,000 patients worldwide that are impacted by this sudden and life-altering disease. Read the full announcement: https://lnkd.in/ePQJQzyr 

FLORetina is underway in Florence, Italy! We’re excited to engage the ophthalmology community about our registrational ARCHER II program and the underlying rationale for vonaprument as a potential vision-sparing treatment for those with dry AMD with Geographic Atrophy. Leading experts will be reviewing data from our Phase 2 ARCHER study and the rationale for our ongoing global Phase 3 ARCHER II study, designed to evaluate the first ever treatment for GA to protect vision. Our conference line-up includes: Dec 4 EYENOVATE We Are in the Midst of a New Treatment Category: Dry AMD Innovation Update with Kim Reed Dec 5 ARCHER II: Study Design and Rationale with Mark Barakat Dec 6 Breakfast Symposium: Neuroinflammation, Neurodegeneration, and New Perspectives in Dry AMD with GA with Francesco Bandello, Prof. Paulo Eduardo Stanga and Daniela Bacherini Updates from the ARCHER Clinical Study with Daniela Bacherini Panel discussion: Future therapies for dry AMD, biomarkers and regulatory processes with Lori Taylor See more on our publications page and join in live if you are onsite in Florence.